Literature DB >> 17928158

Food-elicited increases in cortical acetylcholine release require orexin transmission.

D Frederick-Duus1, M F Guyton, J Fadel.   

Abstract

The corticopetal basal forebrain cholinergic system (BFCS) is crucial for normal attentional function and cortical acetylcholine release is increased by stimuli with high motivational salience. Projections from the lateral hypothalamus to the basal forebrain have been previously described and have been hypothesized to relay interoceptive information to this area but little is known about the phenotypic and functional nature of hypothalamic modulation of the BFCS. We have previously shown that orexin (hypocretin) fibers from the hypothalamus distribute densely among basal forebrain choline acetyltransferase-positive neurons and that intrabasalis administration of orexin A increases cortical acetylcholine release. Here, we used in vivo microdialysis to test the hypothesis that the orexin system is necessary for activation of the BFCS in response to a food-related stimulus in food-restricted rats. Elimination of the majority of orexin neurons with the toxin orexin B-saporin significantly blunted the cholinergic response to presentation of palatable food in these animals. Similar effects were seen in animals acutely pretreated with the orexin 1 receptor antagonist, SB-334867, which also increased feeding latency. Collectively, these data suggest that orexin interactions with the BFCS may be a critical component of the neurobiological substrates by which interoceptive cues bias the allocation of attentional resources toward exteroceptive stimuli related to homeostatic challenges.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928158     DOI: 10.1016/j.neuroscience.2007.07.061

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  28 in total

Review 1.  Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.

Authors:  Jim R Fadel
Journal:  Behav Brain Res       Date:  2010-02-16       Impact factor: 3.332

Review 2.  Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity.

Authors:  Angie M Cason; Rachel J Smith; Pouya Tahsili-Fahadan; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Physiol Behav       Date:  2010-03-23

Review 3.  Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention.

Authors:  J Fadel; J A Burk
Journal:  Brain Res       Date:  2009-08-21       Impact factor: 3.252

4.  Aging-related alterations in orexin/hypocretin modulation of septo-hippocampal amino acid neurotransmission.

Authors:  E M Stanley; J R Fadel
Journal:  Neuroscience       Date:  2011-08-22       Impact factor: 3.590

5.  Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.

Authors:  R B Gibbs; A M Chipman; R Hammond; D Nelson
Journal:  Horm Behav       Date:  2011-08-26       Impact factor: 3.587

Review 6.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

7.  Role of orexin/hypocretin in conditioned sucrose-seeking in rats.

Authors:  Angie M Cason; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

8.  Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine.

Authors:  Ravi K Pasumarthi; Jim Fadel
Journal:  Brain Res Bull       Date:  2008-10-23       Impact factor: 4.077

9.  Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist.

Authors:  Angie M Cason; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2013-03-15       Impact factor: 4.530

Review 10.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.